FHTX - Company ID 0001822462
The table below shows Foghorn Therapeutics Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $3.27M | $8.15M | $7.56M | $5.95M | $7.81M | $6.89M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $18.26M | $20.00M | $21.79M | $21.63M | $24.69M | $23.80M |
Foghorn Therapeutics Inc. reported annual revenue of $30.91M for fiscal year 2025. That is up 36.8% from $22.60M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $430.00K (FY 2020) to $30.91M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $6.58M |
| $6.65M |
| $6.86M |
| $7.24M |
| $6.97M |
| $7.33M |
| Operating income | -$21.57M | -$18.50M | -$21.10M | -$22.91M | -$23.85M | -$26.63M |
| Income tax | - | - | - | - | $0.00 | $0.00 |
| Net income | -$19.88M | -$15.85M | -$17.94M | -$18.83M | -$19.12M | -$22.98M |
| EPS (diluted) | -$0.29 | -$0.25 | -$0.28 | -$0.30 | -$0.31 | -$0.45 |